The UK NICE HTA process can have a positive effect on medical device businesses even before a positive decision is made. That is the experience of surgery products innovator Olympus Medical Systems, a top-30 company globally that is laying down a marker in its approach to clinical and cost effectiveness.
Submitting the TURis (transurethral resection in saline) procedure for approval by the National Institute for Care Excellence (NICE) was not among Olympus Medical Systems Group’s initial UK plans for progressing the benign prostatic hyperplasia (BPH) treatment technology.
Indeed, it was relatively late – mid-2013 – when the Southend-on-Sea, UK subsidiary of the Japanese multinational decided to send...
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
